These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26177509)

  • 61. A robust xenotransplantation model for acute myeloid leukemia.
    Sanchez PV; Perry RL; Sarry JE; Perl AE; Murphy K; Swider CR; Bagg A; Choi JK; Biegel JA; Danet-Desnoyers G; Carroll M
    Leukemia; 2009 Nov; 23(11):2109-17. PubMed ID: 19626050
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
    Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
    Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
    Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
    Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Entinostat prevents leukemia maintenance in a collaborating oncogene-dependent model of cytogenetically normal acute myeloid leukemia.
    Ramsey JM; Kettyle LM; Sharpe DJ; Mulgrew NM; Dickson GJ; Bijl JJ; Austin P; Mayotte N; Cellot S; Lappin TR; Zhang SD; Mills KI; Krosl J; Sauvageau G; Thompson A
    Stem Cells; 2013 Jul; 31(7):1434-45. PubMed ID: 23592435
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics.
    Ghanem H; Tank N; Tabbara IA
    Am J Hematol; 2012 Jan; 87(1):69-77. PubMed ID: 22072438
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Identification of predictive genetic signatures of Cytarabine responsiveness using a 3D acute myeloid leukaemia model.
    Xu H; Muise ES; Javaid S; Chen L; Cristescu R; Mansueto MS; Follmer N; Cho J; Kerr K; Altura R; Machacek M; Nicholson B; Addona G; Kariv I; Chen H
    J Cell Mol Med; 2019 Oct; 23(10):7063-7077. PubMed ID: 31449347
    [TBL] [Abstract][Full Text] [Related]  

  • 67. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.
    Gaidzik VI; Teleanu V; Papaemmanuil E; Weber D; Paschka P; Hahn J; Wallrabenstein T; Kolbinger B; Köhne CH; Horst HA; Brossart P; Held G; Kündgen A; Ringhoffer M; Götze K; Rummel M; Gerstung M; Campbell P; Kraus JM; Kestler HA; Thol F; Heuser M; Schlegelberger B; Ganser A; Bullinger L; Schlenk RF; Döhner K; Döhner H
    Leukemia; 2016 Nov; 30(11):2160-2168. PubMed ID: 27137476
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Deregulation of miR-1, miR486, and let-7a in cytogenetically normal acute myeloid leukemia: association with NPM1 and FLT3 mutation and clinical characteristics.
    Seyyedi SS; Soleimani M; Yaghmaie M; Ajami M; Ajami M; Pourbeyranvand S; Alimoghaddam K; Akrami SM
    Tumour Biol; 2016 Apr; 37(4):4841-7. PubMed ID: 26526573
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
    Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
    J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement.
    Pigazzi M; Manara E; Buldini B; Beqiri V; Bisio V; Tregnago C; Rondelli R; Masetti R; Putti MC; Fagioli F; Rizzari C; Pession A; Locatelli F; Basso G
    Haematologica; 2015 Mar; 100(3):e99-101. PubMed ID: 25480496
    [No Abstract]   [Full Text] [Related]  

  • 71. Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia.
    Falini B; Martelli MP
    Best Pract Res Clin Haematol; 2015; 28(2-3):90-7. PubMed ID: 26590764
    [TBL] [Abstract][Full Text] [Related]  

  • 72. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
    Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
    Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
    [TBL] [Abstract][Full Text] [Related]  

  • 73.
    Olofsen PA; Touw IP
    Mol Cells; 2020 Feb; 43(2):139-144. PubMed ID: 32041395
    [TBL] [Abstract][Full Text] [Related]  

  • 74. RUNX1 variant as a genetic predisposition factor for acute myeloid leukemia.
    Javadlar M; Dastar S; Gharesouran J; Ghafouri-Fard S; Hosseinzadeh H; Moradi M; Mazraeh SA; Nasiri Ganjineh Ketab F; Rezamand A; Hiradfar A; Taheri M; Rezazadeh M
    Exp Mol Pathol; 2020 Aug; 115():104440. PubMed ID: 32294461
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia.
    McCormack E; Mujić M; Osdal T; Bruserud Ø; Gjertsen BT
    Blood; 2013 Feb; 121(7):e34-42. PubMed ID: 23243270
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Stromal cells downregulate miR-23a-5p to activate protective autophagy in acute myeloid leukemia.
    Ganesan S; Palani HK; Lakshmanan V; Balasundaram N; Alex AA; David S; Venkatraman A; Korula A; George B; Balasubramanian P; Palakodeti D; Vyas N; Mathews V
    Cell Death Dis; 2019 Sep; 10(10):736. PubMed ID: 31570693
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML.
    Drenberg CD; Shelat A; Dang J; Cotton A; Orwick SJ; Li M; Jeon JY; Fu Q; Buelow DR; Pioso M; Hu S; Inaba H; Ribeiro RC; Rubnitz JE; Gruber TA; Guy RK; Baker SD
    Nat Commun; 2019 May; 10(1):2189. PubMed ID: 31097698
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Improved chemotherapy modeling with RAG-based immune deficient mice.
    Wunderlich M; Manning N; Sexton C; Sabulski A; Byerly L; O'Brien E; Perentesis JP; Mizukawa B; Mulloy JC
    PLoS One; 2019; 14(11):e0225532. PubMed ID: 31747424
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease.
    Kohlmann A; Nadarajah N; Alpermann T; Grossmann V; Schindela S; Dicker F; Roller A; Kern W; Haferlach C; Schnittger S; Haferlach T
    Leukemia; 2014 Jan; 28(1):129-37. PubMed ID: 23958918
    [TBL] [Abstract][Full Text] [Related]  

  • 80. TP53 mutated AML subclones exhibit engraftment in a humanized bone marrow ossicle mouse model.
    Pabst G; Lind K; Graf R; Zebisch A; Stölzel F; Döhner K; Heitzer E; Reinisch A; Sill H
    Ann Hematol; 2020 Mar; 99(3):653-655. PubMed ID: 32002654
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.